Breakthrough obesity therapy in development
Retatrutide, the latest candidate from pharmaceutical leader Eli Lilly, is demonstrating unprecedented weight-loss results in clinical studies, with participants shedding up to 25% of their body weight. This next-generation medication builds on the success of the company’s existing dual-acting therapy tirzepatide (marketed as Zepbound for obesity and Mounjaro for type 2 diabetes), which itself advanced the field beyond Novo Nordisk’s GLP-1-based drugs semaglutide (Ozempic/Wegovy). Where tirzepatide targets both GLP-1 and GIP receptors, retatrutide introduces a third hormone—glucagon—to the therapeutic mix.
All three hormones—GLP-1, GIP, and glucagon—play interconnected roles in metabolic regulation. They influence blood glucose control, appetite signaling, caloric intake, and downstream energy metabolism. Understanding their distinct and overlapping actions is key to appreciating how retatrutide may offer superior efficacy compared to earlier treatments.
GIP is produced by K cells located in the upper portion of the small intestine and is primarily recognized for its role in stimulating insulin secretion in response to elevated blood glucose. However, its functions extend beyond insulin regulation: GIP aids in breaking down triglycerides, promotes satiety signals in the brain, and helps manage hypoglycemic responses by prompting glucagon release when blood sugar drops too low.
Glucagon, secreted by pancreatic alpha cells, generally opposes the effects of GLP-1 and GIP. Its most well-known function is to raise blood sugar levels during hypoglycemia by triggering the release of glucose and fatty acids. Interestingly, glucagon also plays a supportive role in postprandial states—enhancing insulin production, slowing gastric emptying, and modulating lipid metabolism.
GLP-1 remains the most widely studied of the three. Produced by L cells in the distal small intestine and colon, GLP-1 boosts insulin release in response to dietary carbohydrates while promoting feelings of fullness and delaying stomach emptying. It also encourages fat breakdown in adipose tissue and works synergistically with GIP to stimulate adiponectin—a hormone that improves insulin sensitivity and reduces inflammation.
